A Universal Bacteriophage T4 Nanoparticle Platform to Design Multiplex SARS-CoV-2 Vaccine Candidates by CRISPR Engineering
V. B. Rao, J. Zhu, N. Ananthaswamy, S. Jain, H. Batra, W.-C. Tang, D. A. Lewry, M. L. Richards, S. A. David, P. B. Kilgore, J. Sha, A. Drelich, C.-T. Tseng, A. K. Chopra
Abstract
A "universal" vaccine design platform that can rapidly generate multiplex vaccine candidates is critically needed to control future pandemics. Here, using SARS-CoV-2 pandemic virus as a model, we have developed such a platform by CRISPR engineering of bacteriophage T4. A pipeline of vaccine candidates were engineered by incorporating various viral components into appropriate compartments of phage nanoparticle structure. These include: expressible spike genes in genome, spike and envelope epitopes as surface decorations, and nucleocapsid proteins in packaged core. Phage decorated with spike trimers is found to be the most potent vaccine candidate in mouse and rabbit models. Without any adjuvant, this vaccine stimulated robust immune responses, both TH1 and TH2 IgG subclasses, blocked virus-receptor interactions, neutralized viral infection, and conferred complete protection against viral challenge. This new type of nanovaccine design framework might allow rapid deployment of effective phage-based vaccines against any emerging pathogen in the future.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A Modular Bacteriophage T4 Nanoparticle Platform Enables Rapid Design of Dual COVID-19-Flu Mucosal Vaccines
Jingen Zhu, Jian Sha, … Venigalla Basaveswara Rao·Small SciencePeer-reviewed·Jan 28, 2025
- Design and proof-of-concept for targeted phage-based COVID-19 vaccination strategies with a streamlined cold-free supply chain
D. I. Staquicini, F. H. F. Tang, … R. Pasqualini·bioRxiv·Mar 15, 2021
- Phage-like particle vaccines are highly immunogenic and protect against pathogenic coronavirus infection and disease
B. J. Davenport, A. Catala, … T. E. Morrison·bioRxiv·Nov 8, 2021
- Rapid Development of a Mucosal Nanoparticle Flu Vaccine by Genetic Engineering of Bacteriophage T4 using CRISPR-Cas
M. Li, C. Chen, … P. Tao·Antiviral ResearchPeer-reviewed·Sep 1, 2023
- A bacteriophage-based, highly efficacious, needle and adjuvant-free, mucosal COVID-19 vaccine
- Single-component, self-assembling, protein nanoparticles presenting the receptor binding domain and stabilized spike as SARS-CoV-2 vaccine candidates